STOCK TITAN
  1. Home
  2. News
  3. ASRT

Assertio Holdings, Inc. - ASRT STOCK NEWS

Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.

Assertio Holdings, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company headquartered in Lake Forest, Illinois. The company is dedicated to advancing patient care through the commercialization of differentiated products in the areas of neurology, orphan, and specialty medicines. Assertio's portfolio includes three FDA-approved products:

  • Gralise: Extended-release tablets for the management of postherpetic neuralgia.
  • CAMBIA: A solution for the acute treatment of migraine attacks with or without aura in adults.
  • Zipsor: Liquid-filled capsules for the relief of mild to moderate pain.

In August 2023, Assertio completed the acquisition of Spectrum Pharmaceuticals, Inc., bringing the innovative ROLVEDON™ to its portfolio. This addition is poised to diversify Assertio’s revenue base and enhance its commercial capabilities. Despite some challenges, including competition from generic drugs, Assertio remains committed to leveraging its digital non-personal sales model to drive growth and efficiency.

Financially, Assertio reported substantial cash flow from operations and maintained a robust cash position. The company continues to explore strategic acquisitions and licensing opportunities to expand its portfolio and drive long-term growth. Recent leadership changes and the appointment of experienced executives underscore Assertio’s commitment to optimizing its commercial strategies and maintaining financial stability.

Assertio’s forward-looking strategy involves not only enhancing its current product offerings but also advocating for patient access to medications through legislative efforts. The company’s non-personal promotional model and strategic acquisitions ensure its adaptability in a competitive market. For more detailed financial data and corporate updates, visit Assertio's investor relations website.

News

ASSERTIO INVESTOR DEADLINE APPROACHING

Rhea-AI Summary
Investors who suffered losses exceeding $25,000 in Assertio (ASRT) between March 9, 2023, and November 8, 2023, are encouraged to contact Faruqi & Faruqi for potential claims. The investigation alleges false statements by Assertio executives, impacting profitability and stock performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
-
News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Assertio Holdings, Inc. (ASRT) granted 16,498 restricted stock units and 18,654 stock options to two newly-hired employees, with the options having an exercise price of $1.14 per share and vesting equally annually over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
-
News

Assertio Holdings, Inc. Announces Leadership Transition

Rhea-AI Summary
Assertio Holdings, Inc. (NASDAQ: ASRT) announces the stepping down of CEO Dan Peisert and the appointment of Heather Mason as interim CEO. Heather Mason, a current board member with extensive pharmaceutical and healthcare industry experience, will lead the company as it conducts a search for a permanent chief executive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.4%
Tags
management
News

Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors

Rhea-AI Summary
Assertio Holdings, Inc. (NASDAQ: ASRT) announced the appointment of Sravan Emany, the Chief Financial Officer of Ironwood Pharmaceuticals, to its Board of Directors, expanding the board to seven seats. Mr. Emany's extensive experience in pharmaceuticals and financial leadership is expected to bring depth to the board and contribute to the company's growth and transformation, delivering meaningful shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
management
-
News

Assertio Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
ASRT: Assertio Holdings, Inc. announces financial results for Q3 2023, reporting a cash balance of $76.9 million and the acquisition of Spectrum. The company experienced a net loss of $279.5 million, with net product sales increasing to $35.1 million. Rolvedon net product sales were $7.1 million for the two months following the acquisition. The addition of Rolvedon diversifies and extends the company's portfolio duration, but the loss of Indocin exclusivity and Rolvedon results below expectations drove significant charges to net income.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.19%
Tags
earnings
-
News

Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Summary
Specialty pharmaceutical company, Assertio Holdings, Inc., will release its third quarter 2023 financial results on November 8, 2023, after the market close. A live webcast of the earnings conference call will be hosted by Assertio's management at 4:30 p.m. Eastern Time. The webcast replay will be available on Assertio's investor website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Assertio Holdings, Inc. grants restricted stock units and stock options to a newly-hired employee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Assertio Holdings grants RSUs and stock options to newly-hired employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
Assertio Holdings, Inc. has granted 82,341 restricted stock units (RSUs) and 92,591 stock options to eight newly-hired employees. The RSUs and options were granted as inducements for their employment and are subject to continued service. The options have an exercise price of $5.69 per share and vest equally over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
News

Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition

Rhea-AI Summary
Specialty pharmaceutical company Assertio Holdings, Inc. reported a 13% increase in net product sales for the second quarter, reaching $40.1 million. The company generated $18.6 million in cash flow from operations during the same period. The recent acquisition of Spectrum Pharmaceuticals is expected to significantly increase adjusted EPS in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.61%
Tags
acquisition earnings

FAQ

What is the current stock price of Assertio Holdings (ASRT)?

The current stock price of Assertio Holdings (ASRT) is $0.8859 as of December 20, 2024.

What is the market cap of Assertio Holdings (ASRT)?

The market cap of Assertio Holdings (ASRT) is approximately 81.2M.

What products does Assertio Holdings, Inc. offer?

Assertio offers FDA-approved products such as Gralise, CAMBIA, and Zipsor for neurological and pain management conditions.

What is the significance of Assertio’s acquisition of Spectrum Pharmaceuticals?

The acquisition adds ROLVEDON™ to Assertio’s portfolio, diversifying revenue streams and enhancing commercial capabilities.

How does Assertio promote its products?

Assertio utilizes a digital non-personal promotional model to efficiently promote its products across multiple therapeutic categories.

What are some of Assertio's recent financial highlights?

In the second quarter of 2023, Assertio reported strong cash flow from operations and maintained a substantial cash position.

Who are some of the key leadership figures at Assertio?

Dan Peisert serves as President and CEO, and recent appointments include Ajay Patel as CFO and Paul Schwichtenberg in a senior commercial role.

What challenges does Assertio face with generic competition?

Assertio faces competition from generic versions of its products, impacting sales and necessitating strategic management and adaptation.

What is Assertio’s strategy for long-term growth?

Assertio focuses on strategic acquisitions, expanding its product portfolio, and leveraging its commercial platform to drive long-term growth.

How can investors access information about Assertio?

Investors can visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx for financial reports and updates.

What role does Assertio play in legislative advocacy?

Assertio is involved in advocating for patient access to medications and addressing issues related to pharmacy benefit managers and healthcare costs.

What is Assertio’s approach to sales and marketing?

Assertio employs a non-personal promotional model along with traditional sales forces to market its products effectively.

Stock ASRT logo
Assertio Holdings, Inc.

Nasdaq:ASRT

ASRT Rankings

#4556 Ranked by Market Cap
N/A Ranked by Dividends

ASRT Stock Data

81.18M
92.85M
2.62%
31.94%
6.55%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
LAKE FOREST